|
Hrd in ovarian cancer: Defined today, evolving for the future. |
|
|
|
Honoraria - Astellas Pharma; AstraZeneca; Genomic Health; Janssen-Cilag; Roche |
Consulting or Advisory Role - AstraZeneca; Diaceutics; Genomic Health; Janssen-Cilag |
Speakers' Bureau - Astellas Pharma; AstraZeneca; Diaceutics; MSD; Roche |
Research Funding - STRATIFYER Molecular Pathology |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Diaceutics; Genomic Health; Janssen-Cilag; MSD; Roche |
|
|
Employment - Konica Minolta Precision Medicine |
Consulting or Advisory Role - Agilent; Bristol-Myers Squibb; Daiichi Sankyo; Diaceutics; Loxo; Merck; Roche/Genentech; Ventana Medical Systems |
Speakers' Bureau - Genentech/Roche |
|
|
Stock and Other Ownership Interests - Abbott/AbbVie |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
Stock and Other Ownership Interests - Diaceutics |